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Decreased Ras–Mitogen-Activated Protein Kinase Signaling
May Cause DNA Hypomethylation in
T Lymphocytes From Lupus Patients
Chun Deng, Mariana J. Kaplan, Jun Yang, Donna Ray, Zhiyong Zhang, W. Joseph McCune,
Samir M. Hanash, and Bruce C. Richardson
Objective. Previous studies have shown that in-
hibiting T cell DNA methylation causes a lupus-like
disease by modifying gene expression. T cells from
patients with lupus exhibit diminished levels of DNA
methyltransferase (MTase) enzyme activity, hypo-
methylated DNA, and changes in gene expression simi-
lar to those exhibited by T cells treated with methylation
inhibitors, suggesting that DNA hypomethylation may
contribute to human lupus. Since it is known that DNA
MTase levels are regulated by the ras–mitogen-activated
protein kinase (MAPK) pathway, this study sought to
determine whether decreased ras-MAPK signaling
could account for the DNA hypomethylation in lupus T
cells.
Methods. DNA MTase messenger RNA (mRNA)
from lupus patients and from healthy controls was
quantitated by Northern analysis, and ras-MAPK sig-
naling was determined by immunoblotting with antibod-
ies to the activated forms of extracellular receptor–
associated kinase (ERK). Results were compared with
those in T cells in which ras-MAPK signaling was
inhibited with a soluble inhibitor of MAPK ERK 1
(MEK1).
Results. T cells from patients with active lupus
had diminished DNA MTase mRNA levels and de-
creased signaling through the ras-MAPK pathway. In-
hibiting signaling through the ras-MAPK pathway with
the MEK1 inhibitor decreased DNA MTase mRNA and
enzyme activity to the levels seen in lupus T cells, and
resulted in DNA hypomethylation resembling that seen
in lupus T cells.
Conclusion. These results suggest that a decrease
in signaling through the ras-MAPK pathway may be
responsible for the decreased MTase activity and DNA
hypomethylation in patients with lupus.
Although the primary defect in idiopathic human
lupus remains unknown, the phenomenon of drug-
induced lupus suggests that drug-induced biochemical
changes can lead to the development of lupus-like
diseases. Thus, elucidation of the mechanisms by which
drugs induce lupus may provide clues to the pathogen-
esis of the idiopathic disease. Our group has demon-
strated that some lupus-inducing drugs, including pro-
cainamide and hydralazine, inhibit T cell DNA
methylation (1). We have also shown that various agents
that inhibit DNA methylation in T cells, including
procainamide, hydralazine, 5-azacytidine, and ultraviolet
light, induce leukocyte function–associated antigen 1
(LFA-1) overexpression (2,3), which makes T cells au-
toreactive (3,4). Finally, we have demonstrated that
adoptive transfer of T cells made autoreactive by treat-
ment with DNA methylation inhibitors (2,4–6) or by
transfection with LFA-1 (4) is sufficient to cause a
lupus-like disease in unirradiated syngeneic mice. To-
gether, these studies indicate that one mechanism caus-
ing a lupus-like disease is the induction of T cell DNA
hypomethylation, with subsequent effects on LFA-1
expression and autoreactivity.
To determine the relevance of these studies to
human lupus, we investigated T cell DNA methylation in
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lupus. We obtained evidence that T cells from patients
with active lupus have hypomethylated DNA and an
autoreactive T cell subset that overexpresses LFA-1
(7,8). These observations have been confirmed by inde-
pendent groups (9,10). We have also reported that T
cells from lupus patients have a significant decrease in
DNA (cytosine-5-)-methyltransferase (MTase) activity,
the enzyme mediating maintenance DNA methylation
(11). Since treatment with procainamide, a competitive
DNA MTase inhibitor, results in a similar decrease in
enzyme activity (12), the reduced DNA MTase activity
observed in lupus T cells may be an important step in the
development of lupus. However, the basis for the re-
duced MTase activity in lupus is unknown.
We have demonstrated that DNA methyltrans-
ferase 1 (Dnmt1) levels increase following T cell stimu-
lation, and our group, as well as others, has reported that
Dnmt1 levels are regulated through the ras–mitogen-
activated protein kinase (MAPK) signaling pathway and
activator protein 1 (AP-1) sites (13–16). The studies
presented in this report were undertaken to determine
the role of ras-MAPK signaling in the reduced DNA
MTase activity and DNA hypomethylation in lupus T
cells. We provide evidence that a decrease in signaling
through the ras-MAPK pathway may be responsible for
the decreased MTase activity and for the hypomethyl-
ated DNA in lupus.
PATIENTS AND METHODS
Cells and cell culture. Peripheral blood mononuclear
cells (PBMC) were isolated from the venous blood of healthy
controls, patients with rheumatoid arthritis (RA), and patients
with active and inactive lupus, using density gradient centrifu-
gation as previously described (7). The clinical parameters of
these subjects are described in Table 1. Patients with RA met
the American College of Rheumatology (ACR; formerly, the
American Rheumatism Association) criteria for RA (17), and
patients with lupus met the ACR criteria for systemic lupus
erythematosus (SLE) (18). Lupus disease activity was assessed
as previously described (19) or by the Systemic Lupus Activity
Measure (SLAM) (20). Lupus was considered inactive if the
activity index was ,1 or the SLAM was #5. PBMC were
stimulated with 1 mg/ml phytohemagglutinin (PHA; Burroughs
Wellcome, Greenville, NC) and cultured in interleukin-2
(IL-2) for 7–10 days as previously described (7). Exceptions are
noted in the text. In some experiments, the CD81 population
was depleted by lysis with anti-CD8 (PharMingen, San Diego,
CA) and complement (Pel-Freeze, Brown Deer, WI) using
published protocols (21), and purity was checked by staining
with anti–CD4–fluorescein isothiocyanate followed by flow
cytometric analysis. Jurkat cells were cultured as previously
described (1). Where indicated, the cells were treated with PD
98059 (New England Biolabs, Beverly, MA), a selective inhib-
itor of MAPK extracellular receptor–associated kinase (ERK)
1 (MEK1) (22). Proliferation was measured using tritiated
thymidine (3H-TdR) incorporation as previously described (1).
Flow cytometric cell cycle analysis. For cell cycle
analysis, peripheral blood T cells were stimulated with PHA
and IL-2 as above, then the cells were stained with propidium
iodide (Sigma, St. Louis, MO) as previously described (8). The
stained cells were analyzed on a Coulter ELITE flow cytome-
ter (Hialeah, FL), and the percentage of cells in G0/G1,S, and
G2/M was determined by DNA content.
RNA isolation and Northern analysis. Total RNA was
isolated from T cells using TRIzol reagents from Gibco BRL
(Gaithersburg, MD). Twenty micrograms of total RNA was
electrophoresed in 1% agarose, 2.2M formaldehyde gels and
transferred to nylon membranes (Micron Separations, West-
boro, MA). Care was taken to include RNA from at least 2
normal controls on each membrane and to calculate the
expression of RNA relative to these controls, to avoid variabil-
ity due to technical differences such as efficiency of random
priming and hybridization. The membranes were fixed by
baking for 2 hours at 80°C and hybridized with a 2.5-kb human
Dnmt1 complementary DNA (cDNA) fragment (encoding the
39 catalytic domain), kindly donated by Dr. Stephen Baylin
(23), or a previously described 2.0-kb b-actin cDNA fragment
(8). The cDNA probes were labeled by random priming
according to the manufacturer’s suggestions (Boehringer
Mannheim Biochemicals, Indianapolis, IN) with a-32P-dCTP.
After hybridization, the membranes were exposed to Kodak
radiographic film or developed on a PhosphorImager (Molec-
ular Dynamics, Sunnyvale, CA). Results are calculated as the
ratio of the Dnmt1 band intensity to that of b-actin. Where
indicated, the blots were also restripped and hybridized with a
cDNA encoding a fragment of histone H4 (24). For compari-
son between groups, the mean of this ratio was determined for











NSAID Steroids Anti-malarial CYC AZA MTX Gold
RA 10 7/3 50 6 11 (36–69) 6 4 4 0 0 4 1
Inactive SLE 16 13/3 35 6 13 (18–65) 2 13 14 2 3 0 0
Active SLE 12 10/2 39 6 14 (18–61) 2 12 8 2 1 1 0
* NSAID 5 nonsteroidal antiinflammatory drug; CYC 5 cyclophosphamide; AZA 5 azathioprine; MTX 5 methotrexate; RA 5 rheumatoid
arthritis; SLE 5 systemic lupus erythematosus.
398 DENG ET AL
the normal controls, and the results from individual patients
are expressed as a percentage of this mean value.
Measurement of MAPK activation. Cultured T cells
were treated with 50 ng/ml phorbol myristate acetate (PMA;
Sigma) with or without 50 ng/ml ionomycin (Sigma) for 15
minutes, then harvested and disrupted by sonication. Insoluble
material was removed by centrifugation at 15,000g for 20
minutes, and the supernatant was recovered. Proteins were
fractionated through 10–20% polyacrylamide gradient gels
(Ready gels; Bio-Rad, Hercules, CA) using 25 mg protein per
lane, then electrophoretically transferred to polyvinylidene
difluoride membranes (Immobilon-P; Millipore, Bedford,
MA). Total MAPK and activated MAPK were quantitated
using antibodies to the activated, dually phosphorylated form
of human ERKs 1 and 2 (Anti–ACTIVE MAPK; Promega,
Madison, WI) and previously described protocols (15). Since
the monoclonal antibodies (mAb) to the dually phosphory-
lated forms of ERKs 1 and 2 react only with the activated form
of the proteins, MAPK activation is proportional to the
intensity of the band produced by this antibody. Controls
included isotype-matched irrelevant antibodies, and similar
blots were hybridized with an mAb to ERKs 1 and 2, obtained
from Zymed (South San Francisco, CA). Band intensity was
measured by densitometry as described (8). The ratio of
activated to total MAPK was then determined for each subject,
and results are presented as the ratio of PMA-treated to
untreated preparations. Care was taken to include at least 1
control for each patient on every blot.
Measurement of DNA MTase activity. DNA MTase
enzyme activity was measured as previously described (7),
except that 2 mg of a hemimethylated synthetic oligonucleotide
was used as substrate (25). All determinations were performed
in triplicate.
Measurement of genomic deoxymethylcytosine (dmC)
content. An index of genomic dmC content was obtained by
digesting 4 mg of genomic DNA with the isoschisomers Hpa II
and Msp I (both from Sigma), then fractionating the fragments
by electrophoresis. Hpa II only cleaves unmethylated CCGG
sequences, while Msp I cleaves CCGG sequences regardless of
their methylation status. The fractionated DNA was stained
with propidium iodide, and staining intensity was quantitated
by densitometry between 2 kb and 3 kb. The results are
expressed as the ratio of the Hpa II to Msp I digests, which
increases as DNA demethylates and is more readily digested by
Hpa II. Sss I assays were similarly used to obtain an index of
genomic dmC content, performed as previously described by
our group (16). Sss I catalyzes the transfer of methyl groups
from S-adenosylmethionine to unmethylated dC residues in
CpG pairs. Using S-adenosyl-L-[methyl-3H]methionine as the
methyl donor, 3H-TdR incorporation is inversely proportional
to the extent of DNA methylation (16).
Statistical analysis. The significance of differences
between groups was determined using analysis of variance
(ANOVA) or Student’s t-test. Regression analysis was per-
formed with SySTAT software (Evanston, IL).
RESULTS
Decreased Dnmt1 messenger RNA (mRNA) lev-
els in lupus T cells. To determine if Dnmt1 mRNA
levels are decreased in lupus T cells, PBMC were
isolated from 7 patients with active lupus, 8 patients with
inactive lupus, 5 patients with RA, and normal controls.
The control population consisted of 17 healthy individ-
uals (44% women and 56% men), ages 32 6 7 years
(mean 6 SD; range 22–47 years). To measure Dnmt1
expression, the PBMC were first stimulated with PHA
and IL-2 as described previously (7). Stimulation is
essential because little, if any, Dnmt1 mRNA is ex-
pressed in unstimulated T cells (15). RNA was isolated,
and DNA MTase mRNA was measured by Northern
analysis. At least 2 normal control PBMC samples were
included on every gel. The filters were then stripped,
rehybridized with a b-actin cDNA, and developed as
autoradiograms. b-actin was chosen as a control because
its expression does not change in lupus T cells (26). To
confirm that b-actin levels are not altered in lupus T
cells, the b-actin band intensities were compared be-
tween the patients with active lupus and the healthy
controls, and expressed as the mean ratio of lupus to
controls. This ratio was 1.09 6 0.33 (mean 6 SEM).
Representative Northern blots are shown in Figure 1A.
All subjects demonstrated Dnmt1 transcripts of
the same size. Band intensities were quantitated by
densitometry, and relative Dnmt1 levels were calculated
as the ratio of the intensity of the Dnmt1 band to that of
the b-actin band for each subject. In Figure 1B, the
results are expressed relative to the mean band intensity
ratio of normal controls, arbitrarily defined as 100%.
The results demonstrate that DNA MTase mRNA levels
in patients with active lupus were ;50% lower than
those in healthy controls and RA patients as well as
patients with inactive lupus (P 5 0.034 overall by
ANOVA; P , 0.05 for active lupus versus each of the
other 3 groups by pairwise post hoc comparison). This
abnormality was detectable for up to 10 days in culture.
These mRNA levels are consistent with our prior activity
measurements that showed an ;50% decrease in DNA
MTase enzyme activity in lupus patients relative to
healthy controls and RA patients (7).
The decrease in Dnmt1 mRNA in the T cells
from patients with active lupus could not be attributed to
corticosteroids, because similar numbers of patients with
active and inactive lupus were receiving this drug (Table
1). Furthermore, we have reported that corticosteroids
do not affect DNA methylation (7). More subjects with
inactive lupus than those with active disease were receiv-
ing antimalarial agents, suggesting that these agents were
also not contributing to the decrease in Dnmt1 mRNA
levels in those with active disease. Similar numbers of
patients were also receiving cyclophosphamide. There were
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similar numbers of women in the active and inactive lupus
groups, thus arguing against a sex-specific effect. In addi-
tion, no significant differences in Dnmt1 mRNA levels
were observed between healthy men and women (112 6
17% versus 92 6 12% [mean 6 SEM] for 5 men and 7
women, respectively; compared on the same gels).
Since T cells from patients with active lupus are
relatively anergic (for review, see ref. 27), it is possible
that the decreased Dnmt1 levels reflected a lower per-
centage of proliferating cells. To exclude this possibility,
cell cycling, as determined by propidium iodide staining,
was measured in the stimulated T cells from 5 healthy
controls, 5 patients with active lupus, and 4 patients with
RA (Figure 2). No differences were seen, indicating that
the decrease in DNA MTase was not due to differences
in the kinetics of cell cycling.
We then asked if the decrease in Dnmt1 could be
due to decreased ras-MAPK signaling. T cells from
lupus patients with active and inactive disease and from
RA patients were stimulated with PHA and IL-2 as
Figure 2. Cell cycle analysis of activated T cells from lupus patients
and controls. Phytohemagglutinin- and interleukin-2–stimulated T
cells from healthy controls (n 5 5), rheumatoid arthritis (RA) patients
(n 5 4), or patients with active systemic lupus erythematosus (SLE;
n 5 5) were analyzed by propidium iodide staining and flow cytometric
analysis. Results represent the mean and SEM percentage of cells from
the subjects in each group.
Figure 1. DNA (cytosine-5)-methyltransferase messenger RNA
(mRNA) levels in lupus patients and controls. A, Peripheral blood
mononuclear cells (PBMC) from 2 patients with active systemic lupus
erythematosus (SLE), 2 patients with rheumatoid arthritis (RA), and
3 healthy controls (Nl) were stimulated with phytohemagglutin and
interleukin-2 as described in Patients and Methods. RNA was then
isolated, fractionated by agarose gel electrophoresis, transferred to
nylon membranes, hybridized with a 32P-labeled complementary DNA
(cDNA) encoding the 39 half of human DNA methyltransferase 1
(Dnmt1), then developed as an autoradiogram (upper panel). The
membranes were then stripped and rehybridized with a 32P-labeled
b-actin cDNA (lower panel). B, PBMC from 7 patients with active
lupus, 8 with inactive lupus, 5 with RA, and 17 normal controls were
stimulated and Dnmt1 and b-actin mRNA were detected as in A. The
ratios of Dnmt1 to actin band densities were normalized to the average
of the ratios from at least 2 healthy controls included on each blot.
Each point represents a single subject, and some of the points overlap.
Bars show the mean 6 SEM of the group.
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Figure 3. Decreased mitogen-activated protein kinase (MAPK) phos-
phorylation in lupus T cells. A, T cells from a healthy control (N) or
from patients (P) with active or inactive systemic lupus erythematosus
(SLE) or rheumatoid arthritis (RA) were stimulated with phytohemag-
glutinin and interleukin-2 as in Figure 1. Aliquots of cells were treated
with 50 ng/ml phorbol myristate acetate (PMA) for 15 minutes, then
treated (1PMA) and untreated cells were lysed and proteins separated
by sodium dodecyl sulfate–polyacrylamide gel electrophoresis using 25
mg protein per lane. The fractionated proteins were transferred to
polyvinylidene difluoride membranes and developed as immunoblots
using antibodies to the activated, dually phosphorylated form of
human extracellular receptor–associated kinases 1 and 2 (Active
MAPK) or to framework determinants (Total MAPK). B, Quantitative
immunoblot analysis of activated and total MAPK was performed as
described in Patients and Methods, using T cells from 18 healthy
controls, 5 patients with RA, 8 patients with inactive lupus, and 5
patients with active lupus, and the ratio of activated to total MAPK
was determined for unstimulated and PMA-stimulated cells from each
subject. Results are presented as the ratio of PMA-stimulated to
unstimulated preparations, and represent the mean and SEM of the
determinations within each group. C, Regression analysis comparing
the Systemic Lupus Activity Measure (SLAM) score of the patients
with lupus with the degree of MAPK phosphorylation.
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before. The cells were then treated with PMA, and total
MAPK was quantitated by immunoblotting. PMA was
used, rather than T cell receptor crosslinking agents,
because others have reported abnormalities in early
signaling events in lupus T cells (28), which would
confound interpretation of the results. No differences in
the amount of total MAPK protein was observed be-
tween the groups (105%, 99%, and 87%, for active
lupus, inactive lupus, and RA T cells, respectively,
relative to normal controls). Parallel gels were reacted
with an mAb that is reactive with the dually phosphor-
ylated, activated forms of ERKs 1 and 2.
Figure 3A shows that PMA treatment caused sig-
nificantly less MAPK activation in T cells from a represen-
tative lupus patient relative to that in a healthy control. The
addition of ionomycin gave identical results (not shown).
Kinetic studies demonstrated that both lupus patients and
controls had optimal MAPK activation at 15 minutes. For
reference, similar studies using T cells from patients with
inactive lupus and RA are also shown (Figure 3A), and the
results resembled those in the controls. Similar studies
were performed on T cells from 18 healthy controls, 5
patients with RA, 8 patients with inactive lupus, and 5
patients with active lupus. The healthy controls consisted of
10 men and 8 women, age 32 6 7 years (mean 6 SD; range
21–49 years). Figure 3B compares the relative amounts of
activated MAPK in untreated and PMA-treated T cells
from the lupus patients and controls, adjusted for total
MAPK protein content from each patient. While PMA
caused an increase in MAPK phosphorylation in T cells
isolated from all groups, the increase in T cells from lupus
patients was the smallest, and significantly less than that in
normal controls (P 5 0.01 by Student’s t-test).
The effect of disease activity on MAPK activation
was tested by comparing SLAM scores with MAPK
Figure 4. Decreased MAPK phosphorylation in CD41 lupus T cells.
PBMC were isolated from 5 healthy controls, 3 patients with inactive
lupus, and 4 patients with active lupus. CD41 T cells were depleted by
treatment with anti-CD8 plus complement, and MAPK activation was
studied as in Figure 3B. Cells were ;98% CD41 at the time of analysis
by cytofluorography. Bars show the mean and SEM. See Figures 1 and
3 for definitions.
Figure 5. Effect of phytohemagglutin (PHA) stimulation on MAPK
signaling in control and lupus T cells. A, PBMC from a healthy control
and a patient with active lupus were cultured alone (2) or stimulated
with interleukin-2 and PHA (1), and 30 minutes later, active MAPK
was measured as in Figure 3 (upper panel). Total MAPK was also
measured as described in Figure 3, analyzed using a duplicate gel
(lower panel). B, PBMC from 4 controls and 3 patients with active
lupus were stimulated with PHA and analyzed as in A. Bars show the
mean and SEM of the ratio of activated to total MAPK, as in Figure
3. See Figures 1 and 3 for other definitions.
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activation. Figure 3C shows that as disease activity
increased, the degree of MAPK phosphorylation de-
creased significantly (slope 20.47, P 5 0.004). This
suggests that ras-MAPK signaling is decreased in T cells
from patients with active lupus, and may contribute to
the decrease in DNA MTase activity. This defect was
also stable in culture for up to 10 days.
Since these studies were performed on polyclonal
populations containing both CD41 and CD81 cells, it
was important to determine if the same results could be
obtained using purified CD41 T cells. CD81 cells were
removed by cytolytic depletion, and then the cells were
stimulated and cultured as before. These cells were
routinely 98% CD41 by flow cytometric analysis. Figure
4 compares MAPK phosphorylation in PMA-stimulated
CD41 cells from 5 healthy controls, 3 patients with
inactive lupus, and 4 patients with active lupus. The
CD41 T cells from patients with active lupus had
significantly less MAPK phosphorylation relative to that
in healthy controls (P , 0.05).
To determine if the defect in MAPK signaling
was reflected by differences in the basal phosphorylation
of ERKs 1 and 2 in the unstimulated T cells, the ratio of
activated to total MAPK was also compared between
controls and patients, for unstimulated cells only. There
was no difference in this ratio between controls and
patients with RA or patients with inactive lupus (mean 6
SEM 1.00 6 0.33 and 1.51 6 0.33 in RA and inactive lupus
patients, respectively, relative to paired controls). In con-
trast, there was relatively less basal MAPK activation in
the T cells from patients with active lupus (0.69 6 0.12)
(P 5 0.049 versus controls by Student’s paired t-test).
It was possible that the defect in MAPK signaling
was detectable only with PMA stimulation, but not with
stimulation using ligands of cell surface receptors. To
exclude this possibility, the effect of PHA stimulation on
MAPK activation was examined. Preliminary studies
demonstrated that MAPK activation was maximal 30
minutes after the addition of PHA. PBMC from 3
patients with active lupus and 4 normal controls (59–
83% CD21) were stimulated with PHA and IL-2 for 30
minutes, and MAPK activation was then measured.
Figure 5A shows representative immunoblots from 1
patient and 1 control, and Figure 5B shows the average
Figure 6. Effect of decreased MAPK signaling on Dnmt1 mRNA and DNA methylation. A, Jurkat cells were treated with the
indicated concentrations of PD 98059, and 90 minutes later, mRNA was isolated and analyzed for DNA (cytosine-5)-
methyltransferase (MTase) and b-actin expression as described in Figure 1, then stripped and restudied for histone H4
expression. Results are expressed as the DNA MTase to b-actin ratio or the DNA MTase to H4 ratio in treated/untreated cells,
and are representative of 3 experiments. B, Jurkat cells were treated with the indicated concentrations of the MAPK
extracellular receptor–associated kinase 1 (MEK1) inhibitor, and 48 hours later, DNA was isolated, digested with Hpa II or Msp
I, then fractionated by electrophoresis and stained with ethidium bromide. Results are presented as the ratio of the Hpa II to
Msp I integrated intensities between 2 kb and 3 kb, and represent the mean 6 SEM of 3 independent experiments. See Figures
1 and 3 for other definitions.
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ratio of activated to total MAPK in the subjects (P 5
0.011). The results indicate that a signaling defect re-
sembling that detected using PMA in lupus T cells is
detectable with PHA stimulation as well, and is present
in freshly isolated PBMC.
Effect of decreased ras-MAPK signaling on T cell
DNA methylation. To determine the functional signifi-
cance of decreased ras-MAPK signaling on T cell DNA
methylation, we compared Dnmt1 mRNA expression,
enzyme activity, and genomic dmC content in Jurkat T
cells treated with PD 98059, a selective MEK1 inhibitor.
At the concentrations used in this study, this agent does
not affect the activity of at least 18 other known kinases,
including those involved in the c-Jun N-terminal kinase
(JNK) and p38 cascades, and a .80% inhibition of
MEK1 activity is usually achieved at 50 mM (22).
Figure 6A demonstrates that the MEK1 inhibitor
decreased the levels of Jurkat mRNA by ;50% relative
to those with b-actin and histone H4 (a cell cycle–
specific gene), similar to the decrease seen in the lupus
patients. Figure 6B compares genomic dmC content in
untreated and MEK1 inhibitor–treated Jurkat cells. For
this assay, DNA was digested with Hpa II and Msp I. Hpa
II recognizes and cuts unmethylated, but not methyl-
ated, CCGG sequences, while Msp I cuts CCGG se-
quences regardless of their methylation status. Results
are expressed as the ratio of Hpa II to Msp I digests, and
the ratio increases as DNA becomes more hypomethyl-
ated and thus more readily digested by Hpa II. The
results show that treatment with PD 98059 decreased
total genomic dmC content (20 mM versus 0 or 0.2 mM;
P , 0.01).
To confirm that inhibiting ras-MAPK signaling
will also decrease DNA MTase enzyme activity, Jurkat
cells were treated with 20 mM PD 98059. The level of
DNA MTase enzyme activity per mg nuclear protein in
the treated cells was 62 6 2% of controls (mean 6 SEM
of 3 determinations, each performed in triplicate) (P ,
0.01 by univariate t-test of the mean), thus correlating
with mRNA levels.
These results were confirmed by treating PHA-
stimulated, IL-2–dependent normal T cells with 20 mM
PD 98059, then measuring DNA MTase activity (Figure
7). PD 98059 decreased enzyme activity by 58 6 12%
(mean 6 SEM of triplicate determinations) (P , 0.01).
In contrast, no effect was seen on the proliferation of
these cells, indicating that the decrease did not represent
an effect on cell cycling. Sss I assays were used to
compare dmC content in the treated and untreated cells.
Jurkat cells, as well as normal T cells similarly stimulated
with PHA and IL-2, were treated with 20 mM PD 98059
for 24 hours, then DNA was isolated and Sss I–catalyzed
3H-TdR incorporation was compared. PD 98059 treat-
ment increased 3H-TdR incorporation by 10.2 6 1.3%
in normal T cells and by 8.8 6 0.2% in Jurkat T
cells (mean 6 SEM of duplicate determinations), indicat-
ing that inhibiting ras-MAPK signaling inhibits DNA
methylation in normal T cells as well as in Jurkat cells.
The observation that inhibiting ras-MAPK signal-
ing causes decreased Dnmt1 mRNA levels and enzyme
activity, as well as producing DNA hypomethylation,
argues strongly that the decrease in DNA MTase activity
and the DNA hypomethylation seen in lupus T cells is
due to decreased signaling through the ras-MAPK
pathway.
DISCUSSION
The goal of these studies was to determine the
mechanism causing a decrease in DNA MTase enzyme
activity and DNA hypomethylation in lupus T cells.
Since inhibiting DNA MTase was previously shown to be
Figure 7. Effect of an MEK1 inhibitor on DNA MTase activity in normal
T cells. T cells were stimulated with phytohemagglutinin and interleukin-2
as in Figure 1, then cultured alone (untreated) or with 20 mM PD 98059
(treated) for 24 hours. DNA MTase activity was measured as described in
Patients and Methods. Results represent the counts per minute (CPM) of
3H-thymidine incorporated in hemimethylated synthetic oligonucleotides
per mg protein, and are presented as the mean and SEM of 3 determi-
nations. Proliferation was measured at the same time by culturing 20,000
untreated or treated cells with 3H-thymidine for 2 hours in microtiter
wells, then 3H-thymidine incorporation into DNA was assessed. See
Figure 6 for definitions.
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sufficient to cause a lupus-like disease (5,6), early exper-
iments sought evidence for an endogenous inhibitor.
However, mixing studies gave no evidence for an inhib-
itor in lupus T cells (Richardson B et al: unpublished
results). More recently, we reported that DNA MTase
levels depend on T cell stimulation, and that the levels
are regulated, in part, by the ras-MAPK signaling path-
way (15,16). In the present studies, we therefore asked if
regulation of Dnmt1 by this pathway might be abnormal
in lupus T cells.
DNA MTase levels were compared using acti-
vated T cells. This was necessary because Dnmt1 is not
expressed in unstimulated T cells (15). The results
demonstrated a decrease in the amount of Dnmt1
mRNA in lupus T cells, which was almost identical in
magnitude to the decrease in enzyme activity previously
reported (7). Since we have previously reported a close
correlation between the levels of the T cell DNA MTase
enzyme and Dnmt1 mRNA levels (15), this suggests that
the decrease in enzyme activity is due to a decrease in
the level of the mRNA. It should be noted that T cells
from patients with active lupus can be refractory to
stimulation (27). To avoid this problem, which could
result in an artifactual decrease in DNA MTase, the cells
were stimulated with PHA and IL-2, then activation was
compared by propidium iodide cell cycling studies (also
done in a previous study [7]). This strategy confirmed
equivalent stimulation between groups. Thus, the DNA
MTase decrease is not due to inefficient stimulation of
the lupus T cells. Furthermore, the decrease persisted
for up to 10 days in culture, suggesting a stable biochem-
ical abnormality.
We next asked if ras-MAPK signaling might be
defective in these cells. Decreased MAPK phosphoryla-
tion following PMA stimulation was observed in T cells
from patients with active lupus, implying that the de-
crease in DNA MTase could be due to a decrease in
ras-MAPK signaling. Inhibiting MEK1 activation caused
a similar 50% decrease in Jurkat Dnmt1 mRNA and a
corresponding decrease in enzyme activity in Jurkat and
normal T cells, and induced DNA hypomethylation
resembling that seen in lupus T cells, further suggesting
that impaired signaling causes the decrease in Dnmt1
enzyme activity and DNA hypomethylation characteris-
tic of lupus. It should be noted that the MEK1 inhibitor
did not completely suppress Dnmt1 expression, implying
the existence of other elements providing the remaining
promoter activity. Indeed, there is a CpG island, typical
of housekeeping genes and containing promoter ele-
ments (29), located 59 to the MTase gene AP-1 sites
implicated in ras-MAPK signaling (30), which may also
drive this expression.
Other investigators have made observations con-
sistent with the notion of defective ras-MAPK signaling
in lupus. For example, IL-2 secretion has been shown to
be defective in lupus T cells (31), and IL-2 is regulated,
in part, by the ras-MAPK pathway (32,33). Other inves-
tigators, using electrophoretic mobility shift assays, have
demonstrated that lupus T cells contain less of the AP-1
transcription factor (34), the activation of which is also
regulated by this pathway (35). How decreased signaling
through the ras-MAPK pathway relates to other signal-
ing abnormalities in lupus T cells (36,37) is unknown at
this time.
The mechanism causing the decrease in signaling
is unknown. The strategy of stimulating with PMA and
measuring MAPK phosphorylation suggests that the
defect may lie in protein kinase C, ras, raf, or MEK.
Interestingly, preliminary evidence suggests that JNK
pathway signaling is normal in patients with active SLE
(38), raising the possibility that the defect is unique to
the MAPK pathway. The precise mechanisms causing
the decrease in signaling, as well as its relationship to
lymphocyte subsets and disease activity, will be the
subject of future studies.
Recently, additional enzymes modifying DNA
methylation have been identified. These include
Dnmt3a and Dnmt3b, which mediate de novo methyl-
ation (39), as well as a putative demethylase (40). The
identification of these enzymes implies that cells have
the ability to modify methylation patterns in unstimu-
lated cells, as well as during mitosis through the effects
on Dnmt1. Whether these enzymes are expressed in
mature T lymphocytes is unknown, and their potential
role in the DNA hypomethylation associated with lupus
is yet to be determined. However, the observation that
inhibiting ras-MAPK signaling decreases Dnmt1 expres-
sion to the same extent as that observed in lupus, and
that this decrease correlates with DNA hypomethylation
in vitro and in vivo, suggests that the defect in Dnmt1 is
the primary reason for DNA hypomethylation in SLE.
In summary, these studies suggest a novel mech-
anism that could contribute to the development of
idiopathic lupus, and perhaps to the characteristic dis-
ease flares occurring after stresses such as infections
(41). In this model, T cells are stimulated to divide by
exogenous antigens, but a failure of the cell to ade-
quately up-regulate Dnmt1 results in DNA hypomethy-
lation with subsequent T cell autoreactivity, lasting until
the cells more completely remethylate the DNA, or until
T cells are suppressed by other immune mechanisms.
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Since inhibiting DNA MTase with lupus-inducing drugs
has similar effects on T cells, and T cells treated with
DNA methylation inhibitors cause a lupus-like disease in
vivo, these results suggest a common mechanism for
drug-induced and idiopathic lupus.
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